Literature DB >> 18679603

Effect of sodium tanshinone II A sulfonate on phosphorylation of extracellular signal-regulated kinase 1/2 in angiotensin II-induced hypertrophy of myocardial cells.

Shu-sheng Li1, Jun Feng, Zhi Zheng, Qian-sheng Liang.   

Abstract

OBJECTIVE: To observe the effects of sodium tanshinone II A sulfonate (STS) on angiotensin II (Ang II)-induced hypertrophy of myocardial cells through the expression of phosphorylated extracellular signal-regulated kinase (p-ERK1/2).
METHODS: In the primary culture of neonatal rat myocardial cells, the total protein content in myocardial cells was determined by coomassie brilliant blue and the protein synthesis rate was measured by [3H]-Leucine incorporation as indexes for hypertrophy of myocardial cells. The expression of p-ERK1/2 was determined using Western blot and immunofluorescence labeling.
RESULTS: (1) The total protein and protein synthesis rate increased significantly in contrast to the control group after the myocardial cells were stimulated by Ang II (1 micromol/L) for 24 h; STS markedly inhibited the increment of the total protein level induced by Ang II and the syntheses of protein. (2) After pretreatment of myocardial cells with Ang II (1 micromol/L) for 5 min, the p-ERK1/2 protein expression was increased, with the most obvious effect shown at about 10 min; pretreatment of myocardial cells with STS at different doses (2, 10, 50 micromol/L) for 30 min resulted in obvious inhibition of the expression of p-ERK1/2 stimulated by Ang II in a dose-dependent manner. (3) After the myocardial cells were stimulated by Ang II (1 micromol/L), the immunofluorescence of ERK1/2 rapidly appeared in the nucleus. The activation and translocation process of ERK1/2 induced by Ang II was blocked distinctly by STS.
CONCLUSION: STS inhibited the myocardial cell hypertrophy induced by Ang II, and the mechanism may be associated with the inhibition of p-ERK1/2 expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679603     DOI: 10.1007/s11655-008-0123-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  8 in total

1.  Protective effect of Salvia miltiorrhiza on angiotensin II-induced hypertrophic responses in neonatal rat cardiac cells.

Authors:  X Ouyang; K Takahashi; K Komatsu; N Nakamura; M Hattori; A Baba; J Azuma
Journal:  Jpn J Pharmacol       Date:  2001-12

Review 2.  Signalling pathways in cardiac myocyte hypertrophy.

Authors:  P H Sugden
Journal:  Ann Med       Date:  2001-12       Impact factor: 4.709

3.  Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts.

Authors:  C A van Kesteren; H A van Heugten; J M Lamers; P R Saxena; M A Schalekamp; A H Danser
Journal:  J Mol Cell Cardiol       Date:  1997-08       Impact factor: 5.000

Review 4.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

5.  Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy.

Authors:  T Yamazaki; I Komuro; S Kudoh; Y Zou; I Shiojima; T Mizuno; H Takano; Y Hiroi; K Ueki; K Tobe
Journal:  Circ Res       Date:  1995-08       Impact factor: 17.367

6.  Inhibitory effect of antisense oligodeoxynucleotide to p44/p42 MAPK on angiotensin II-induced hypertrophic response in cultured neonatal rat cardiac myocyte.

Authors:  Shi-Qin Zhang; Bo Ding; Zhao-Gui Guo; Yun-Xia Li
Journal:  Acta Pharmacol Sin       Date:  2004-01       Impact factor: 6.150

Review 7.  Hypertrophy of the heart: a new therapeutic target?

Authors:  Norbert Frey; Hugo A Katus; Eric N Olson; Joseph A Hill
Journal:  Circulation       Date:  2004-04-06       Impact factor: 29.690

Review 8.  Cardiac hypertrophy: the good, the bad, and the ugly.

Authors:  N Frey; E N Olson
Journal:  Annu Rev Physiol       Date:  2003-01-09       Impact factor: 19.318

  8 in total
  5 in total

1.  Tanshinone IIA: a potent, natural anti-carcinogenic agent for the management of systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  Chin J Integr Med       Date:  2009-04-29       Impact factor: 1.978

2.  Tanshinone II A inhibits dendritic cell-mediated adaptive immunity: potential role in anti-atherosclerotic activity.

Authors:  Hong-zhan Li; Yong-heng Lu; Guang-sheng Huang; Qi Chen; Qiang Fu; Zhi-liang Li
Journal:  Chin J Integr Med       Date:  2012-09-21       Impact factor: 1.978

3.  Antiatherogenic and Anti-Ischemic Properties of Traditional Chinese Medicine Xinkeshu via Endothelial Protecting Function.

Authors:  Xu Tao; Peng Jing-Bo; Zhang Wen-Tong; Zhao Xin; Zhang Tao-Tao; Yang Shi-Jun; Fang Lei; Zou Zhong-Mei; Cai Da-Yong
Journal:  Evid Based Complement Alternat Med       Date:  2011-10-10       Impact factor: 2.629

4.  Tanshinone IIA: A Promising Natural Cardioprotective Agent.

Authors:  Qinghua Shang; Hao Xu; Li Huang
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-06       Impact factor: 2.629

Review 5.  Targeting Oxidative Stress and Endothelial Dysfunction Using Tanshinone IIA for the Treatment of Tissue Inflammation and Fibrosis.

Authors:  Tsuo-Cheng Lu; Yi-Hsiu Wu; Wei-Yu Chen; Yu-Chiang Hung
Journal:  Oxid Med Cell Longev       Date:  2022-04-07       Impact factor: 7.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.